Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).

@article{Bruenke2005EffectiveLO,
  title={Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).},
  author={Joerg Bruenke and Karin Barbin and Susanne Kunert and Peter A. Lang and Matthias Pfeiffer and Kristin Stieglmaier and Dietrich Niethammer and Bernhard Stockmeyer and Matthias Peipp and Roland Repp and Thomas Valerius and Georg H. Fey},
  journal={British journal of haematology},
  year={2005},
  volume={130 2},
  pages={218-28}
}
A recombinant bispecific single-chain fragment variable antibody (bsscFv), directed against the B-cell antigen CD19 and the low affinity Fc-receptor FcgammaRIII (CD16), was designed for use in the treatment of patients with leukaemias and lymphomas. The Fc-portions of whole antibodies were deliberately eliminated in this construct to avoid undesired effector functions. A stabilised bsscFv, ds[CD19 x CD16], was generated, in which disulphide bonds bridging the respective variable light (VL) and… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
In antibody - dependent cellular cytotoxicity experiments , ds[CD19 x CD16 ] mediated specific lysis of both CD19-positive malignant human B - lymphoid cell lines and primary tumour cells from patients with B - cell chronic lymphocytic leukaemia or B - cell acute lymphoblastic leukaemia .
All Topics